Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab + trastuzumab + utomilumab + vinorelbine
- Development stage
- Phase 2
- Lead developer
- Merck KGaA
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a combination therapy consisting of four distinct agents: 1. Avelumab - a PD-L1 inhibitor (immune checkpoint inhibitor) 2. Trastuzumab - an anti-HER2 monoclonal antibody 3. Utomilumab - a 4-1BB (CD137) agonist 4. Vinorelbine - a vinca alkaloid chemotherapy agent that works by interfering with cell division by binding to tubulin and preventing microtubule formation This combination likely represents an experimental regimen combining immunotherapy (avelumab and utomilumab), targeted therapy (trastuzumab), and chemotherapy (vinorelbine) for treatment of cancer, possibly HER2-positive breast cancer.
02
Targets
TNFRSF9 (CD137 extracellular domain)ERBB2 (Erb-b2 receptor tyrosine kinase 2)CD274 (Programmed cell death protein 1 ligand 1)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on avelumab + trastuzumab + utomilumab + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab + trastuzumab + utomilumab + vinorelbine.